切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2021, Vol. 10 ›› Issue (06): 622 -628. doi: 10.3877/cma.j.issn.2095-3232.2021.06.019

基础研究

MTCL1在肝癌中表达及其对术后复发的影响
林国桢1, 代天星2, 邓铭彬2, 汪国营3,†()   
  1. 1. 518112　深圳市第三人民医院肝脏外科暨肝移植中心；510630　广州，中山大学附属第三医院肝脏外科暨肝移植中心
    2. 510630　广州，中山大学附属第三医院肝脏外科暨肝移植中心
    3. 510120　广州医科大学附属第一医院肝胆外科
  • 收稿日期:2021-08-30 出版日期:2021-09-23
  • 通信作者: 汪国营
  • 基金资助:
    十三五科技重大专项(2017ZX10203205-006-001); 国家自然科学基金(81870449，81770648，81670601); 广东省科技计划项目(2017B020209004); 广州市科技计划项目(2014Y2-00544，2014Y2-00200); 广州市健康医疗协同创新项目(201604020001)

Expression of MTCL1 in hepatocellular carcinoma and its effect on postoperative recurrence

Guozhen Lin1, Tianxing Dai2, Mingbin Deng2, Guoying Wang3,†()   

  1. 1. Department of Hepatobiliary Surgery & Liver Transplantation Center, the Third People's Hospital of Shenzhen, Shenzhen 518112, China; Department of Hepatobiliary Surgery and Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    2. Department of Hepatobiliary Surgery and Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    3. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Received:2021-08-30 Published:2021-09-23
  • Corresponding author: Guoying Wang
全文 ( ) 下载PDF ( )
目的

探讨微管交联因子1（MTCL1）在肝细胞癌（肝癌）中表达及其对术后复发的影响。

方法

回顾性分析2015年10月至2018年12月在中山大学附属第三医院行肝癌切除术的76例患者临床病理资料。其中男66例，女10例；年龄27~68岁，中位年龄51岁。患者均签署知情同意书，符合医学伦理学规定。采用实时定量PCR（QRT-PCR）、Western blot和免疫组化法检测肝癌组织MTCL1 mRNA表达，分析MTCL1 mRNA表达与患者生存预后的关系，并采用TCGA数据库验证。采用细胞划痕实验体外研究MTCL1过表达及siRNA沉默MTCL1后肝癌细胞的迁移能力。两组MTCL1相对表达量比较采用t检验。生存分析采用Kaplan-Meier法和Log-rank检验。

结果

肝癌组织MTCL1 mRNA平均相对表达量为3.47±0.86，明显高于癌旁组织的1.38±0.25（t=2.36，P<0.05）。MTCL1蛋白相对表达量为1.07±0.18，明显高于癌旁组织的0.64±0.04（t=2.64，P<0.05）。免疫组化法检测显示肝癌组织中的MTCL1蛋白高表达。MTCL1 mRNA高、低表达组术后3年无瘤生存率分别为24.7%、52.7%，低表达组无瘤生存明显优于高表达组（χ2= 9.28，P<0.05）。TCGA数据库分析显示高表达组术后总体生存时间较低表达组短（HR=1.500，P<0.05）。细胞划痕实验结果显示，MTCL1过表达组97L肝癌细胞伤口愈合率为（7.79±0.31）%，明显高于空载对照组的（3.21±0.41）%（t=8.89，P<0.05）。MTCL1-siRNA组的Hep-G2肝癌细胞伤口愈合率为（9.12±0.75）%，明显低于阴性对照组的（13.79±0.23）%（t=-5.96，P<0.05）。

结论

肝癌组织MTCL1高表达，MTCL1可促进肝癌细胞迁移，高表达患者肝癌切除术后复发率高，预后差。

关键词: 微管交联因子1, 癌，肝细胞, 细胞迁移, 预后
Objective

To investigate the expression level of microtubule cross-linking factor 1(MTCL1) in hepatocellular carcinoma (HCC) and its effect on the postoperative recurrence of HCC.

Methods

Clinicopathological data of 76 HCC patients who underwent hepatectomy in the Third Affiliated Hospital of Sun Yat-sen University from October 2015 to December 2018 were retrospectively analyzed. Among them, 66 patients were male and 10 female, aged from 27 to 68 years, with a median age of 51 years. The informed consents of all patients were obtained and the local ethical committee approval was received. The expression of MTCL1 mRNA in HCC tissues were detected by quantitative real-time PCR (QRT-PCR), Western blot and immunohistochemical staining. The relationship between MTCL1 mRNA expression and survival of patients was analyzed, and was verified by TCGA database. The migration capability of HCC cells with MTCL1 overexpressing and siRNA-silenced MTCL1 was evaluated by cell scratch test in vitro. The relative expression level of MTCL1 between two groups was compared by t test. Kaplan-Meier method andLog-rank test were performed for survival analysis.

Results

The average relative expression of MTCL1 mRNA in HCC tissues was 3.47±0.86, significantly higher than 1.38±0.25 in the adjacent tissues (t=2.36, P<0.05). The relative expression of MTCL1 protein in HCC tissues was 1.07±0.18, significantly higher than 0.64±0.04 in the adjacent tissues (t=2.64, P<0.05). Immunohistochemical staining detected that MTCL1 protein was highly expressed in HCC tissues. The 3-year tumor-free survival rate was 24.7% in MTCL1 mRNA high expression group, and 52.7% in low expression group, the 3-year tumor-free survival in low MTCL1 mRNA expression group was significantly better than that in high expression group (χ2= 9.28, P<0.05). TCGA database analysis demonstrated that the overall survival in the MTCL1 mRNA high expression group was significantly shorter than that in the low expression group (HR=1.500, P<0.05). Cell scratch test showed that the wound healing rate of MHCC97-L cells in MTCL1 overexpression group was (7.79±0.31)%, significantly higher than (3.21±0.41)% in the empty control group (t=8.89, P<0.05). The wound healing rate of Hep-G2 cells in the MTCL1-siRNA group was (9.12±0.75)%, significantly lower than (13.79±0.23)% in the negative control group (t=-5.96, P<0.05).

Conclusions

MTCL1 is highly expressed in HCC tissues, which can promote the migration of HCC cells. Patients with high expression of MTCL1 likely has high recurrence and poor prognosis.

Key words: Microtubule cross-linking factor 1, Carcinoma, hepatocellular, Cell migration, Prognosis
图1 Western blot检测MTCL1蛋白在肝癌组织和癌旁组织中的表达注：MTCL1为微管交联因子1，T为肝癌组织，N为癌旁组织
图2 免疫组化法检测MTCL1蛋白在肝癌组织中的表达注：示MTCL1蛋白在肝癌组织中高表达；MTCL1为微管交联因子1
表1 MTCL1 mRNA表达与肝癌切除术患者临床病理特征及复发的关系（例）
参数 MTCL1 mRNA χ2值 P值
低表达 高表达
性别     0.451 0.502
  男 35 18    
  女 2 3    
年龄     1.118 0.290
  <60岁 32 15    
  ≥60岁 5 6    
AFP     2.312 0.128
  <400 μg/L 20 7    
  ≥400 μg/L 17 14    
肿瘤直径     2.449 0.118
  <5 cm 22 8    
  ≥5 cm 15 13    
肿瘤数目     0.081 0.776
  单发 26 14    
  多发 11 7    
BCLC分期     4.337 0.037
  A+B期 34 14    
  C期 3 7    
肝癌分化程度     1.045 0.307
  高中分化 33 21    
  低分化 4 0    
血管侵犯     6.009 0.014
  无 34 13    
  有 3 8    
门静脉癌栓     6.186 0.013
  无 36 15    
  有 1 6    
复发     5.688 0.017
  否 24 6    
  是 13 15    
图3 MTCL1 mRNA高表达和低表达患者Kaplan-Meier生存曲线注：MTCL1为微管交联因子1
图4 97L肝癌细胞划痕实验注：MTCL1为微管交联因子1，Vector为空载对照组，OE-MTCL1为MTCL1过表达组
[1]
Bray F, Ferlay J, Soerjomataram I，et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68(6):394-424.
[2]
Ferlay J, Colombet M, Soerjomataram I，et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer，2019，144(8):1941-1953.
[3]
Mizuguchi Y, Takizawa T, Yoshida H，et al. Dysregulated miRNA in progression of hepatocellular carcinoma: a systematic review[J]. Hepatol Res，2016，46(5):391-406.
[4]
Sia D, Villanueva A, Friedman SL，et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology，2017，152(4):745-761.
[5]
Zhu H, Wu J, Shen X. Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes[J]. Scand J Gastroenterol，2017，52(2):209-215.
[6]
Khan FS, Ali I, Afridi UK，et al. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics[J]. Hepatol Int, 2017, 11(1):45-53.
[7]
Kader MA, Satake T, Yoshida M，et al. Molecular basis of the microtubule-regulating activity of microtubule crosslinkingfactor 1[J]. PLoS One, 2017, 12(8):e0182641.
[8]
Haryono SJ, Datasena IGB, Santosa WB，et al. A pilot genome-wide association study of breast cancer susceptibility loci in Indonesia[J]. Asian Pac J Cancer Prev, 2015, 16(6):2231-2235.
[9]
Wang S, Pitt JJ, Zheng Y，et al. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria[J]. Int J Cancer, 2019, 145(12):3321-3333.
[10]
Saraswat S, Rout PK, Kharche SD, et al. Molecular expression of caprine estrogen receptor gene 1 in reproductive and non-reproductive tissues[J]. Reprod Domest Anim, 2016, 51(6):1049-1054.
[11]
Chen L, Li Y, Lin CH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma[J]. Nat Med, 2013, 19(2):209-216.
[12]
Xu R, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11):1155-1161.
[13]
Fu C, Xu X, Lu W, et al. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma[J]. Medicine，2019, 98(42):e17412.
[14]
Su YH, Kim AK, Jain S. Liquid biopsies for hepatocellular carcinoma[J]. Transl Res，2018(201):84-97.
[15]
Hyodo T, Ito S, Asano-Inami E, et al. A regulatory subunit of protein phosphatase 2A, PPP2R5E, regulates the abundance of microtubule crosslinking factor 1[J]. FEBS J，2016，283(19):3662-3671.
[16]
Sato Y, Akitsu M, Amano Y, et al. The novel PAR-1-binding protein MTCL1 has crucial roles in organizing microtubules in polarizing epithelial cells[J]. J Cell Sci，2013, 126(Pt 20):4671-4683.
[17]
Sato Y, Hayashi K, Amano Y, et al. MTCL1 crosslinks and stabilizes non-centrosomal microtubules on the Golgi membrane[J]. Nat Commun, 2014(5):5266.
[18]
Satake T, Yamashita K, Hayashi K, et al. MTCL1 plays an essential role in maintaining Purkinje neuron axon initial segment[J]. EMBO J, 2017, 36(9):1227-1242.
[19]
Ferreira LT, Logarinho E, Macedo JC, et al. SOGA1 and SOGA2/MTCL1 are CLASP-interacting proteins required for faithful chromosome segregation in human cells[J]. Chromosome Res, 2021, 29(2):159-173.
[20]
Garcia J, Lizcano F. KDM4C activity modulates cell proliferation and chromosome segregation in triple-negative breast cancer[J]. Breast Cancer, 2016(10):169-175.
[1] 张哲, 樊俊, 刘文斌, 徐琰. 基于NR3C2相关免疫调节基因的乳腺癌预后模型构建与验证[J]. 中华乳腺病杂志(电子版), 2022, 16(02): 74-83.
[2] 欧雷, 罗之谦, 陈旺文, 龙凯军. 胃癌患者No.14v淋巴结转移或微转移与临床病理特征及预后关系研究[J]. 中华普外科手术学杂志(电子版), 2022, 16(03): 279-282.
[3] 郭宁, 邓天伟, 胡述静. 基于腹腔镜技术的不同吻合方式用于远端胃癌根治术的近中期随访比较[J]. 中华普外科手术学杂志(电子版), 2022, 16(03): 283-286.
[4] 孙号, 谢贻祥, 王永森. 结直肠癌No.253淋巴结转移的危险因素及对预后的影响[J]. 中华普外科手术学杂志(电子版), 2022, 16(03): 315-318.
[5] 雷震, 郭正辉, 唐晨, 彭圣萌, 任艳婷, 吴宛桦, 周杰, 陈勇明, 李凌峰, 黄海, 赖义明. ASF1B通过调控P53相关信号通路促进前列腺癌迁移和增殖的研究[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(03): 262-269.
[6] 阙清扬, 余炯杰, 凌孙彬, 徐骁. 免疫治疗在肝癌肝移植降期治疗中的应用及前景[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 221-224.
[7] 陈泰安, 熊永福, 徐建, 李强, 杨刚, 李敬东. 复杂肝癌腹腔镜肝切除的应用及挑战[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 239-243.
[8] 苟晓雪, 王明达, 薛军, 史鸿云, 张新, 杨田. 立体定向放射治疗在肝细胞癌合并门静脉癌栓中的应用[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 248-251.
[9] 谢静, 毛先海, 杨建辉, 段小辉, 田朕安, 张雄, 高绪照. 再次肝切除与腹腔镜微波消融治疗复发性小肝癌临床疗效比较[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 258-262.
[10] 卢文峰, 付雍, 阎凯, 袁建勇, 陈佩钦, 张海斌. 术后预防性TACE对肝内胆管细胞癌患者预后的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 268-272.
[11] 江哲龙, 魏志鸿, 杜俊杰, 江艺, 吕立志, 杨芳. FOXC2对肝癌肝移植患者预后的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 309-314.
[12] 熊培尧, 唐雨豪, 杨子良, 朱应钦, 王骏成, 徐立. 小鼠VETC（+）肝癌模型构建及索拉非尼对VETC结构的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 315-319.
[13] 原江亮, 江波, 刘海义, 张毅勋, 白文启, 王文渊. 87例肛管直肠恶性黑色素瘤临床分析[J]. 中华结直肠疾病电子杂志, 2022, 11(02): 135-140.
[14] 林影, 李建红, 卢宏全, 陈俊玲. 急性脑梗死患者血清正五聚蛋白3水平与其血脂、认知功能及预后的关系研究[J]. 中华临床医师杂志(电子版), 2022, 16(05): 420-424.
[15] 王加雷, 周海峰, 杨魏, 刘圣, 施海彬, 周卫忠. 不可切除胆道癌致梗阻性黄疸患者行介入术后的生存预测模型建立[J]. 中华介入放射学电子杂志, 2022, 10(02): 169-178.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号